Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Wells Fargo & Co (WFC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Wells Fargo & Co — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Wells Fargo & Co trades at $87.93 (market cap $266.73B). The key difference: Wells Fargo & Co is far larger — about 6.7× Alnylam Pharmaceuticals, Inc.'s market cap, and Wells Fargo & Co pays a 2.07% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | WFC | |
|---|---|---|
Market Cap | $39.89B | $266.73B |
Sector | Health | Financials |
52-Week High | $491.22 | $96.40 |
52-Week Low | $278.09 | $73.42 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Wells Fargo (WFC) trades at $87.12, up 0.24% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows steady revenue growth to $83.70B in 2025 and net income of $21.34B, with a P/E of 13.47 suggesting reasonable valuation. Recent news highlights anticipation for Q2 2026 earnings on July 14, 2026, with analysts expecting EPS of $1.73. The dividend of $0.45 per share was paid in June 2026, supporting income investors.
Outlook is cautiously optimistic with a consensus price target of $99.44, implying 14% upside, though risks include volatile cash flows and regulatory scrutiny. Earnings misses in recent quarters warrant monitoring, but improving net interest income and fee growth could drive positive surprises. Investor sentiment is balanced with 45% buy ratings, but macroeconomic pressures on banks remain a headwind.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
